A Study of JNJ-63733657 in Healthy Japanese Participants
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 24
- Registration Number
- NCT03689153
- Locations
- 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 42
- Registration Number
- NCT03618160
- Locations
- 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Japan
🇯🇵Sumida Hospital, Tokyo, Japan
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 22
- Registration Number
- NCT03547037
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Japan
🇯🇵National Cancer Center Hospital, Chuo-Ku, Japan
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 24
- Registration Number
- NCT03536325
- Locations
- 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Japan
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 19
- Registration Number
- NCT03474679
- Locations
- 🇯🇵
Gunmaken Saiseikai Maebashi Hospital, Maebashi, Japan
🇯🇵The Hospital of Hyogo College of Medicine, Nishinomiya, Japan
🇯🇵Tokai University Hospital, Isehara, Japan
A Study to Assess the Nicotine Pharmacokinetics, Tolerability and Safety With a New Oral Nicotine Replacement Product in Healthy Japanese Smokers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 24
- Registration Number
- NCT03398876
- Locations
- 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Japan
A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 6
- Registration Number
- NCT03242889
- Locations
- 🇯🇵
National Hospital Organization Shibukawa Medical Center, Gunma, Japan
🇯🇵Osaka University Hospital, Osaka, Japan
🇯🇵Nagoya City University Hospital, Nagoya, Japan
A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 8
- Registration Number
- NCT03123848
- Locations
- 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Japan
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 48
- Registration Number
- NCT03002025
A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 33
- Registration Number
- NCT02993250
© Copyright 2024. All Rights Reserved by MedPath